Introduction {#Sec1}
============

Physicians and researchers have been aware of diabetes mellitus heterogeneity for many decades. They well understood that hyperglycemia was just a common feature for a group of distinct disorders with different pathophysiology. First, they learned to distinguish the 2 most prevalent diabetic phenotypes--type 1 diabetes mellitus (T1DM), and type 2 diabetes mellitus (T2DM) \[[@CR1], [@CR2]\]. As soon as in the 1960s and 1970s, some experts realized that medicine was dealing with an even larger complexity of diabetes etiologies \[[@CR3]\]. It was observed that in some families, the disease corresponded to neither insulin-dependent (T1DM), nor non-insulin-dependent (T2DM) diabetes. The affected individuals presented some features of both of the major diabetes forms, such as young age of onset and lack of obesity on the one hand, and clinical insulin independence on the other. This observation led to the description of the first monogenic forms of diabetes, maturity onset diabetes of the young (MODY) \[[@CR4], [@CR5]\]. Over the last decades more such monogenic forms of diabetes have been described \[[@CR6]--[@CR8]\]. It was also revealed that while each of these single gene diabetes forms were rare, they were numerous and, together, created a complex pathophysiological and clinical picture.

Beginning from the early 1990s, discovering the molecular background of monogenic disorders, including diabetes, became almost a routine procedure \[[@CR9]\]. Thus, substantial progress was made in the dissection of the genetic background of monogenic forms of diabetes. The common denominators of these disorders are hyperglycemia and the occurrence of a severe single-gene mutation that causes the disease phenotype. Subsequently, it was possible to establish the specific diagnosis through the analysis of the patient's DNA sequence. However, there are also substantial differences between these monogenic disorders. For example, based on pathophysiology, they may be divided into 2 major groups---associated with either beta cell defect or with severe insulin resistance (Table [1](#Tab1){ref-type="table"}) \[[@CR8], [@CR10]\]. They also vary in respect of mode of inheritance, including autosomal dominant, autosomal recessive, and maternally inherited forms. Nevertheless, even in diseases with the same mode of inheritance interesting differences are observed, as in MODY families diabetes is passed from one generation to the other, while in permanent neonatal diabetes mellitus (PNDM) we observed many cases with spontaneous mutations \[[@CR11]\]. These monogenic disorders are characterized by different ages of disease onset, from infants in PNDM, through adolescents in MODY, to middle aged subjects in some laminopathies \[[@CR5], [@CR8], [@CR10], [@CR11]\]. There are also substantial differences in their prevalence. For example, it is estimated that the proportion of MODY patients may constitute about 1 % of all diabetic cases, which would correspond to half a million patients on the European continent alone \[[@CR12]\]. On the other hand, PNDM is very rare, it affects 1 child in 250 000 live births \[[@CR11]\].Table 1Select important steps in unraveling genetic heterogeneity of monogenic diabetesBeta cell diseaseInsulin resistanceYearDiseaseYearDisease1992--1999HNF4A MODY, GCK, HNF1A MODY, HNF1B MODY, IPF MODY, Neurod1 MODY(formerly MODY 1-6)1988Type A insulin resistance1992MIDD1988Donohue syndrome1998Wolfram syndrome2000Familial partial lipodystrophy2004--2006Potassium channel sub-unit related PNDM2002Generalized lipodystrophy2007Insulin related PNDM

Almost half a century of successful research constitutes an excellent perspective to look at what the single gene diabetes forms have taught us.

Gene Search and Discovery {#Sec2}
=========================

One important lesson that we learned from single gene diabetes is that the gene responsible for the occurrence of diabetes can be identified if appropriate methodology is used. The successful identification of monogenic diabetes genes encouraged and accelerated the genetic studies in T2DM. In general, there were 2 strategies used for the search for monogenic diabetes in the late 1980s and 1990s. The first one was the candidate gene approach, focused on a limited set of genes picked up for the mutation search based on their role in insulin secretion or insulin action. This strategy led to the discovery of the first monogenic diabetes genes---for example insulin receptor and glucokinase \[[@CR13], [@CR14]\]. It soon became clear that a more systematic strategy was necessary to increase the efficacy and success rate of the search for new genes. The strategy called genome-wide linkage study with subsequent positional cloning which led to the identification of the *HNF4A* and *HNF1A* genes, which were found to be responsible for 2 forms of monogenic diabetes, initially called MODY1 and MODY3, respectively \[[@CR15], [@CR16]\]. This discovery pointed to the entire family of transcription factors, leading to further single gene disorder discoveries, which involved *HNF1B, IPF, NEUROD1,* and some other genes \[[@CR17]--[@CR19]\].

The search for complex, common T2DM followed this general scheme seen in monogenic diseases. However, in polygenic diseases, scientists were looking for the associated susceptibility alleles with modest effect, rather than for sequence differences with strong causal effects. Although some sequence differences were identified as increasing the risk of T2DM using candidate gene association study design, for example the Pro12Ala variant of the *PPARG* gene, and the Glu23Lys of the *KCNJ11* gene \[[@CR20], [@CR21]\], this strategy brought many more disappointments than successes. Thus, as for monogenic diabetes, a more systematic strategy became desirable. Initially, researchers employed the same scheme of genome-wide linkage studies with subsequent positional cloning \[[@CR22]\]. As, unlike in monogenic disorders, extended pedigrees were not available, large collections of small families were genotyped \[[@CR22], [@CR23]\]. Unfortunately, this strategy generated a significant amount of inconclusive data, unconfirmed findings, and, in general, was not successful. The only T2DM gene identified by this combined approach was *TCF7L2*, a transcription factor involved in the insulin secretion process \[[@CR24]\]. The solution came together with high-throughput efficient genotyping methodology and a new generation of whole-genome search methods---genome wide association studies (GWAS) \[[@CR25]\]. This systematic approach created a breakthrough and led to the identification of several dozens of genes whose variants confer small effect on T2DM susceptibility \[[@CR26]\].

After the first set of single gene diabetes types was described in the 1990s, some researchers postulated that the possible involvement of these genes in common multifactorial forms of the disease should be tested. The hypothesis assumed that if a gene had been shown to carry a causal variant for monogenic diabetes with high penetrance, it may also include other variants with a detectable effect on T2DM. These variants could have an influence on gene expression or function with their impact being much too low to result in Mendelian disease inheritance but sufficient to modify the risk of a polygenic disease. Such small effect could be detected by case-control association studies. Not surprisingly, the initial studies were based on the candidate-gene strategy and involved genes identified as linked to MODY (*HNF1A, HNF4A*, glucokinase), PNDM (*KCNJ11, ABCC8*), and severe forms of insulin resistance (*PPARG*) \[[@CR20], [@CR27]\]. This phase of research was then followed by GWAS, which confirmed some of the earlier findings and added some new variants in monogenic diabetes genes associated with T2DM \[[@CR26]\]. The list of genes responsible for monogenic forms of diabetes and associated with an increased risk of T2DM in GWAS is presented in Table [2](#Tab2){ref-type="table"}.Table 2Variants within "monogenic diabetes" genes associated with T2DM---either identified or confirmed by large scale association studiesLocusChromosomeMonogenic phenotypeT2DM-associated variant*PPARG*3Insulin resistance syndromePro12Ala*KCNJ11*11PNMD, TNDM, MODYGlu23Lys*ABCC8*11PNMD, TNDM, MODYAla369Ser*HNF1B*17HNF1B MODYrs3110641*WFS1*4Wolfram syndromers10010131, rs6446482*HNF1A*12HNF1A MODYrs7957197*GCK*7GCK MODY, PNDMrs1799884

GWAS identified many loci associated with the risk of T2DM and metabolic traits, such as obesity \[[@CR26]\]. In spite of this substantial progress, the genetic loci so far identified are responsible for only a small portion of the overall genetic heritability of T2DM \[[@CR28]\]. In addition, taken together, genetic risk markers have very limited application in individual risk prediction \[[@CR29]\]. One of the new areas in the search is the identification of low-frequency, intermediate penetrance, moderate to large effect variants \[[@CR30]\].

Whole genome sequencing or exome sequencing are novel approaches based on next generation sequencing \[[@CR31]\]. They found application as a diagnostic tool, screening method for monogenic disorders and complex diseases \[[@CR32]\]. Exome sequencing in diabetes and other common diseases reflects a paradigm shift in contemporary genetic studies: according to the novel hypothesis, T2DM and other polygenic disorders develop on a complex background of multiple rare variants with moderate to high impact on phenotype and variable penetrance, which obscures underlying Mendelian inheritance \[[@CR33]•\]. This suggests that monogenic disorders might be pathogenetically closer to T2DM than it was previously perceived. Genes harboring mutations causative for monogenic diabetes are likely to contain low frequency causal variants in T2DM.

Single Gene Diabetes Pathways and T2DM {#Sec3}
======================================

Rare monogenic forms of diabetes with a single and well defined molecular cause help trace links between faulty genes, biochemical or regulatory dysfunction, and clinical phenotype. These forms can be considered simplified and partial models of T2DM, although, they cannot replicate the complexity of its pathogenesis. The process of insulin secretion is a particularly good illustration of how monogenic models help to understand the pathophysiology of T2DM. Glucose is transported inside pancreatic beta cells via several transporters and undergoes phosphorylation by the enzyme glucokinase, a specific form of hexokinase characterized by a low affinity to glucose and lack of inhibition by the product of catalyzed reaction, glucose-6-phosphate \[[@CR34], [@CR35]\]. The activated glucose enters glycolysis, the tricarboxylic acid cycle, and provides energy for adenosine triphosphate (ATP) synthesis in mitochondria through oxidative phosphorylation. The specific kinetic features of glucokinase, the gatekeeper of ATP synthesis process, make the amount of the ATP produced fairly proportional to the glucose concentration outside the beta cell. When the glucose level is low, the concentration of ATP remains low and ATP-sensitive potassium channels in the beta cell plasmatic membrane remain open. Potassium ion influx in the cell maintains the membrane potential. Increased glucose availability results in increased ATP concentration, closure of the ATP-gated channels, and activation of voltage-gated calcium channels. The influx of calcium in the cell signals for exocytosis of insulin granules \[[@CR36]\].

Nearly every step of this process can be linked to a monogenic model of diabetes. Mutations affecting *GLUT2*, one of the glucose transporters in the human beta cells, result in the Fanconi-Bickel syndrome. This is a phenotypically complex glycogen storage disease with postprandial hyperglycemia or overt diabetes. Abnormal hepatic glucose clearance seems to be the major mechanism of hyperglycemia \[[@CR37]\]. Impaired glucose sensing by beta cells also plays a significant role \[[@CR38]\]. Recently, some very rare cases of PNDM have been linked to the mutations altering GLUT2 \[[@CR39]\]. The finding that patients with homozygous mutations of the gene encoding GLUT2 develop neonatal diabetes suggests that this transporter plays an important role in the physiology of the beta cell. Loss of function mutations in *GCK*, a gene coding for glucokinase, result in a mild form of MODY \[[@CR14]\]. The glucose sensing role of the affected gene product implies an intriguing phenotype: the blood glucose threshold for insulin secretion is increased, but the functional capacity of beta cells is preserved; a rightward shift of the dose-response curve is observed \[[@CR40]\]. In addition, in a very rare biallelic inactivation of *GCK*, a phenotype of PNDM is observed: a complete loss of the capacity to respond to elevated glucose results in a phenotype of very early onset severe diabetes \[[@CR41]\]. The next step in beta cell response to glucose, which is ATP synthesis, is impaired in a monogenic disease affecting mitochondria---maternally inherited diabetes with deafness (MIDD). MIDD results from the sequence differences of the mitochondrial genome and the severity of the diabetic phenotype may vary, from mild hyperglycemia to insulin dependence \[[@CR42], [@CR43]\]. The subsequent step of glucose sensing mechanism, the ATP-sensitive potassium channel consists of 2 subunits: channel-building Kir6.2, encoded by the *KCNJ11* gene, and regulatory SUR1, encoded by the *ABCC8* gene \[[@CR44]\]. Activating mutations of either of these genes, keeping the channel in open conformation result in a diabetic phenotype, most commonly PNDM, less frequently MODY or relapsing diabetes \[[@CR11], [@CR44], [@CR45]\]. Since *KCNJ11* is expressed outside the pancreas, some mutation carriers, in addition to insulin-dependent diabetes, present with neurological features such as developmental delay and muscle weakness \[[@CR11], [@CR44]\].

Beta cells may fail to produce and store a sufficient amount of fully functional hormone in their secretory granules. This happens when the *INS* gene coding for their content, insulin, is affected \[[@CR46]\]. The defective and abnormally folded proinsulin molecule may induce the unfolded protein response and undergo degradation in the endoplasmic reticulum. It has been hypothesized that the resulting endoplasmic reticulum stress leads to beta cell apoptosis. The range of phenotypes varies from some mutations resulting in a complete destruction of beta cells and absolute lack of insulin and PNDM to others producing a MODY-like phenotype \[[@CR47]\].

One of the most common causes of monogenic diabetes are sequence differences of genes encoding transcription factors. Their pathology is associated with impaired growth, differentiation and renewing of beta cells, as well as with an impaired transcription of the insulin gene. Transcription factor autosomal dominant mutations result in MODY. The genes that code for transcription factors associated with monogenic diabetes include *HNF1A, HBF1B, HNF4A, PDX1, NEUROD1,* and some others \[[@CR15]--[@CR19]\]. These transcription factors show varying expression patterns at different stages of pancreas development \[[@CR48]\]. Selected genes and pathways of insulin secretion affected by monogenic diseases are shown in Table [3](#Tab3){ref-type="table"}.Table 3Monogenic defects of insulin secretionGenesFunction of the protein or tRNAPhenotype of mutation carriers*HNF1A, HNF1B, HNF4A, PDX1, NEUROD1, KLF11, PAX4*Involvement in beta cell differentiation, proliferation and insulin synthesisMODY, rarely PNDM if biallelic dysfunction*BLK*Non-receptor tyrosine-kinase regulating insulin synthesisMODY*SLC2A2 (GLUT2)*Glucose transport to beta cellFanconi-Bickel syndrome*GCK*Glucose phosphorylation in the limiting step of ATP production in beta cellMODY, PNDM if biallelic dysfunctionmitochondrial *leucyl tRNA* gene and several other mitochondrial genesMitochondrial ATP synthesisMIDD*KCNJ1, ABCC8*Structure and function of the ATP-sensitive potassium channel of beta cellsPNDM, TNDM, MODY*INS*Coding for insulinPNDM, MODY

Monogenic defects producing insulin resistance, the other fundamental component of the T2DM phenotype, seem to be less explored than single gene defects of insulin secretion. Nevertheless, a few examples of pathophysiological models are also available for severely impaired insulin action. Insulin receptor gene (*INSR*) mutations are linked to several syndromes of generalized insulin resistance. Their clinical presentation may be severe, with short stature, dysmorphic features, and short life expectancy, as in Donohue syndrome and Rabson-Mendenhall syndrome \[[@CR49], [@CR50]\]. These syndromes result from homozygous or compound heterozygous mutations \[[@CR51], [@CR52]\]. A milder form linked to the insulin receptor gene is type A insulin resistance, which may have dominant or recessive inheritance \[[@CR53]\]. The patients may have less pronounced features present in pediatric syndromes, such as enlarged chin, nose, ears, and dental abnormalities. More importantly, phenotypic characteristics of INSR mutations include, in addition to hyperglycemia, other clinical features observed in T2DM and associated disorders, such as acanthosis nigricans, hirsutism, and polycystic ovaries. Mutations in the *AKT2* gene, coding for kinase, which plays a central role in post-receptor insulin signaling, produce insulin resistant diabetes and elevated fasting triglycerides, low HDL cholesterol, and high LDL level, a presentation similar to dyslipidemia accompanying T2DM. Patients also have liver steatosis, resembling the non-alcoholic fatty liver disease in T2DM \[[@CR54]\]. *AKT2* mutation carriers also have reduced adipose tissue content. Congenital partial lipodystrophies resulting from mutations in *LMNA*, coding for nuclear envelope components, lamin A and C, or from mutations in gene coding the peroxisome proliferator activated receptor γ (*PPARG*) are characterized by abnormalities in the lipid profile (hypertriglyceridemia, low HDL-cholesterol), hirsutism, acanthosis nigricans, and hypertension \[[@CR55], [@CR56]\]. In these disorders we observe abnormal body fat distribution, which emphases the role of fat metabolism in the pathogenesis of insulin resistance.

In summary, it is quite clear that exploring monogenic diabetes provided new insights to a better understanding of the pathophysiological events leading to chronic hyperglycemia not only in single gene diabetes but also in complex forms of this disease.

Pharmacogenetics in Diabetes {#Sec4}
============================

Another lesson coming from monogenic models of diabetes is that hypoglycemic treatment may be tailored for some patients based on the etiology of their diseases, which constitutes an example of pharmacogenetics. Pharmacogenetics is a scientific discipline that examines genetic variations that gives rise to differing response to drugs. This includes not only therapeutic efficacy but also toxic side effects of drugs.

Probably the earliest of pharmacogenetics is related to *HNF1A MODY* \[[@CR7], [@CR8], [@CR16]\]. In this monogenic diabetes, pharmacologic treatment is usually inevitable; however, in spite of a frequently young age of diabetes onset, one can use a treatment alternative to insulin. Since sulfonylureas (SU), the oldest group of oral hypoglycemic agents, act on the beta cell and enhance insulin secretion \[[@CR57]\], the notion that the latter group are the drugs of choice in MODY was very appealing. Several case reports from various populations suggested that patients with *HNF1A* MODY were characterized by a specifically prominent therapeutic response to SU \[[@CR58], [@CR59]\]. This hypothesis was eventually confirmed by a double blind, randomized, clinical study that compared the efficacy of gliclazide and metformin in *HNF1A* MODY and complex T2DM \[[@CR60]••\]. *HNF1A* MODY patients showed much a better response to gliclazide than the patients with T2DM and this difference was associated with a great insulin secretion improvement in MODY patients. The effect of metformin on glucose levels in MODY patients was much weaker than for SU. The researchers attributed the findings to the nature of the beta cell defect in MODY, as *HNF1A* is responsible for the expression of genes involved in glucose uptake, glycolysis, and mitochondrial metabolism. SU act downstream to these cellular defects by binding to the *SUR1* subunit of the ATP-dependent potassium channel \[[@CR57]\]. Thus, they are able to overcome the defects underlying this genetic form of diabetes and improve beta cell functioning. Thus, the genetic cause of *HNF1A* MODY is an important determinant of the response to oral hypoglycemic drugs. To date, the study of Pearson et al is the only randomized clinical trial performed in a monogenic population. The pathophysiological similarity suggests that SU are efficient in other MODY forms linked to transcription factors \[[@CR7], [@CR8], [@CR15], [@CR17]--[@CR19], [@CR61]\]. Unlike in transcription factor monogenic diabetes, in *GCK* MODY diet is sufficient in most affected subjects \[[@CR7], [@CR8], [@CR62]\].

In some individuals affected by MIDD, the disease closely mimics T1DM and it requires insulin from the very diagnosis. In many other cases, secretagogues or even a diet alone are sufficient, at least for some time \[[@CR63]\]. Metformin is generally considered contraindicated in MIDD patients because of the potential risk for lactate acidosis. However, this notion is based solely on the knowledge of the MIDD pathophysiology and biguanides mode of action rather than on clinical data.

Another spectacular example of tailoring hypoglycemic treatment to disease etiology is PNDM. Patients with *KCNJ11* mutations are characterized by a very good response to SU treatment. In this form of *KCNJ11*-related PNDM, SU action precisely corrects the mechanism underlying this type of diabetes by closing the activated potassium channel of the beta cells \[[@CR11], [@CR35], [@CR64]\]. Successful transfer from insulin to SU has been accomplished for both adults and children, including infants \[[@CR11], [@CR65], [@CR66], [@CR67]••, [@CR68], [@CR69]\]. In most of these cases, a substantial improvement in glycemic control was seen and no major side effects were reported. The doses of various SU compounds were much higher than usually therapeutically used in T2DM. It was hypothesized that SU use might be particularly useful in the correction of some extra-pancreatic symptoms, such as muscle weakness, or developmental delay. Indeed, recently published data provided evidence for neurological improvement in diabetic Kir6.2 mutation carriers after glibenclamide use \[[@CR70]\]. In addition, most of the patients with a molecular diagnosis of PNDM due to *ABCC8* gene mutations could also be transferred off from insulin to SU \[[@CR11], [@CR47]\]. Unfortunately, we will not find such spectacular examples of pharmacogenetics for forms of diabetes associated with severe insulin resistance and clinical management of these patients remains challenging.

The important question that arises is whether we can translate the therapeutic success from some monogenic forms of diabetes to polygenic ones. Indeed, several common polymorphisms in genes linked to monogenic forms seem to influence the response to pharmacological treatment. The polymorphisms of *KCNJ11* and *TCF7L2* genes were associated with a therapeutic efficacy of SU in patients with T2DM \[[@CR71], [@CR72]\]. The *ABCC8* gene (encoding SUR1) Ser1369Ala variant was found to be associated with antidiabetic efficacy of gliclazide in the Asian population \[[@CR73]\]. The Glu23Lys variant of *KCNJ11* was also associated with risk for severe SU-induced hypoglycemia in T2DM patients \[[@CR74]\]. In a patch-clamp technique based study aimed to analyze nucleotide sensitivity and SU inhibition of recombinant human K~ATP~ channels containing *KCNJ11/ABCC8* variants, the increased sensitivity of the Glu23/Ala1369 variant combination to the SU-gliclazide was found \[[@CR75]\]. However, realistically, we should not expect that in the nearest future pharmacological treatment in T2DM will be based on genetic testing. This stems from the fact that the response to treatment is probably influenced by many variants, each of them having little effect on the drug efficacy. It is possible that future discoveries of rare, major effect variants may add new perspectives for pharmacogenetics in T2DM.

Conclusions {#Sec5}
===========

There are several lessons that we have learned from the monogenic diabetes research. The success in dissecting the molecular cause of rare diabetes forms encouraged and inspired genetic research of complex diabetes. The identification of new pathophysiological pathways for single gene diabetes enabled a better understanding of T2DM mechanisms. Spectacular pharmacogenetics examples in MODY and PNDM give us hope that, sometime in the future, hypoglycemic drugs will be tailored for other forms of diabetes based on their etiologies. Moreover, it seems that there is still some potential in exploring the role of genes in which mutations cause monogenic diabetes in polygenic forms of the disease. The application of novel technologies, including exome sequencing, may be useful. It may happen that the same new technology will be used for the search for novel mutations responsible for monogenic diabetes and "oligogenes" for common types of the disease. There is also a hope that new drugs targeting proteins and pathways altered in some forms of monogenic diabetes will be developed.
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